Indaptus Therapeutics (INDP)

• Market cap: $11.3M
• 1 day: 5.39%
• 5 days: -6.20%
• 1 month: -11.51%
• 3 months: -33.48%
• 6 months: -59.57%
• Year to date: -46.70%
• 1 year: -49.02%
• 5 years: -89.43%
• 10 years: -89.43%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

1.1% less ownership

Funds ownership: 7.04% [Q2] → 5.93% (-1.1%) [Q3]

19% less funds holding

Funds holding: 21 [Q2] → 17 (-4) [Q3]

41% less capital invested

Capital invested by funds: $1.26M [Q2] → $750K (-$514K) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 433% upside
• Avg. target: $8.50 806% upside
• High target: $12 1,179% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target	433% upside $5	Buy Maintained	13 Nov 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	1,179% upside $12	Buy Reiterated	16 Oct 2024